Efficacy and adverse reactions of pembrolizumab combined with chemotherapy in patients with advanced esophageal cancer and its effect on survival
Objective To analyze the efficacy and safety of pembrolizumab combined with chemotherapy in patients with advanced esophageal cancer.Methods Fifty patients with advanced esophageal cancer from the Second People's Hos-pital of Henan Province from January 2019 to March 2022 were divided into control group and observation group(n=25).Patients in control group were treated with paclitaxel combined with cisplatin,and patients in observation group were treated with pembrolizumab on the basis of control group.The clinical efficacy,levels of serum tumor markers,oc-currence of adverse reactions,and 1-year survival rate were compared between the two groups.Results The objective remission rate of observation group(56.00％)was prominently higher than that of control group(28.00％)(P＜0.05).After 1 month of treatment,the serum carcinoembryonic antigen(CEA),high mobility group box 1 protein(HMGB1),and squamous cell carcinoma antigen(SCC-Ag)levels in observation group were significantly lower than those in control group(P＜0.001).There were no significant differences in the incidence of adverse reactions between two groups(P＞0.05).The 1-year survival rate of the observation group(84.00％)was significantly higher than that of the control group(64.00％)(P＜0.05).Conclusion Pembrolizumab combined with chemotherapy had a signifi-cant effect on advanced esophageal cancer patients,could reduce the level of serum tumor markers and improve the sur-vival rate of patients,and had fewer adverse reactions,which was worthy of clinical implementation and utilization.
NETL
NSTL
万方数据
